Theravance Biopharma, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Theravance Biopharma, Inc. (TBPH) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of -$200.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2024-08-08
- Theravance Biopharma, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-06-30 was $0.00.
- Theravance Biopharma, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-03-31 was -$200.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month |
|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$200.00K 10-Q · filed 2024-08-08 | |
| 2023-03-31 | -$200.00K 10-Q · filed 2024-05-15 | $200.00K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |